Bullish
Pfizer's stock price rises to $28.18 amid positive Q2 earnings and FDA approval.
Pfizer's stock price increased to $28.18 following the release of its second-quarter 2026 earnings report, which showed a 3% year-over-year revenue growth to $15.0 billion. Additionally, the U.S. Food and Drug Administration approved Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season, potentially boosting future revenues.
Key points
- Pfizer's Q2 2026 revenue increased by 3% year-over-year to $15.0 billion.
- FDA approved Pfizer and BioNTech's updated COVID-19 vaccine for the 2026-2027 season.
- Pfizer's stock price closed at $28.18, up 0.84% from the previous close.
Sources
AI-generated from public news sources. Not financial advice.
